BioSpace News Archive

Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.

IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, reported financial results for the quarter ended March 31, 2024.

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus standard of care in previously untreated adult patients with mantle cell lymphoma.

Theralase® Technologies Inc. is pleased to announce that it has expanded its clinical team with the hiring of two Clinical Research Associates.

Alvotech announced today that members of management would be participating in the upcoming BofA Securities Healthcare Conference 2024, which will be held on May 14-15, 2024 in Las Vegas, NV.

Ocugen, Inc. today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL.

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.

Arbutus Biopharma Corporation today announced that after a distinguished 38-year career, the Company’s co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024.